ROTTERDAM, Netherlands, GHENT, Belgium, and PRINCETON, N.J.,
July 26, 2011 /PRNewswire/ — arGEN-X, a biopharmaceutical company
focused on the discovery and development of human monoclonal
antibodies from its proprietary SIMPLE Antibody™ platform,
announces it has signed a non-exclusive license agreement with
BioWa Inc., the exclusive worldwide licensor of POTELLIGENT®
Technology.
arGEN-X’s SIMPLE Antibody™ platform is unique in providing
human variable regions of unprecedented diversity, allowing the
rapid selection of antibodies with superb functional potency. In
under two years, these attributes have already been validated
preclinically in seven in vivo and ex vivo models,
highlighting the productivity of the technology.
POTELLIGENT® Technology is a clinically validated approach
to producing monoclonal antibodies (mAbs) with significantly
enhanced antibody-dependent cellular cytotoxicity (ADCC) and tumor
cell killing activity. By combining the power of the SIMPLE
Antibody™ platform with POTELLIGENT® Technology, arGEN-X
expects to increase the intrinsic potency of these mAbs even
further. Under this license agreement, arGEN-X will apply
POTELLIGENT® Technology to its own novel mAbs addressing cancer
and inflammatory disorders and will offer antibodies encompassing
both technologies to its commercial partners.
Commenting on today’s announcement, Tim Van Hauwermeiren, CEO
of arGEN-X, said: “We are applying our proprietary SIMPLE
Antibody™ technology to targets where a selectively potent
antibody interaction works in concert with effector function to
mediate optimal therapeutic effects. The extraordinary diversity of
antibodies generated from our platform allows us to preferentially
select leads with only the highest quality functional properties.
Combining such superior variable regions with constant regions
enhanced by the validated POTELLIGENT® Technology supports
our
‘/>”/>
